Ardelyx
ARDXDrugs in Pipeline
9
Phase 3 Programs
6
Upcoming Catalysts
3
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
3 upcoming, 1 past
ARDX Earnings Report
EPS Est: $-0.05 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How ARDX's past catalysts played out
Tenapanor 5 mg BID
Chronic Idiopathic Constipation (CIC)
Sevelamer Carbonate
Hyperphosphatemia
Tenapanor
Hyperphosphatemia
Phosphate Binder Agents
Hyperphosphatemia
AZD1722
Chronic Kidney Disease
Tenapanor 50 MG
Irritable Bowel Syndrome With Constipation (IBS-C)
RDX5791
Constipation Predominant Irritable Bowel Syndrome
AZD1722 (in-patient)
End Stage Renal Disease
RDX013
Hyperkalemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tenapanor 5 mg BID | Phase 3 | Chronic Idiopathic Constipation (CIC) | - | - |
Sevelamer Carbonate | Phase 3 | Hyperphosphatemia | - | - |
Tenapanor | Phase 3 | Hyperphosphatemia | - | - |
Phosphate Binder Agents | Phase 3 | Hyperphosphatemia | - | - |
AZD1722 | Phase 3 | Chronic Kidney Disease | - | - |
Tenapanor 50 MG | Phase 3 | Irritable Bowel Syndrome With Constipation (IBS-C) | - | - |
RDX5791 | Phase 2 | Constipation Predominant Irritable Bowel Syndrome | - | - |
AZD1722 (in-patient) | Phase 2 | End Stage Renal Disease | - | - |
RDX013 | Phase 2 | Hyperkalemia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Ardelyx's drug pipeline?→
CatalystAlert tracks 9 drug candidates in Ardelyx's (ARDX) pipeline across Phase 3, Phase 2. Its lead program is Tenapanor 5 mg BID (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ardelyx's next FDA catalyst?→
Ardelyx's (ARDX) next tracked catalyst is a Phase 2 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARDX biotech catalysts?→
Add ARDX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ardelyx's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.